Bio

Andrew Cohan is Founder and Partner of Halmos Capital. Previously, Andrew worked at Perry Capital, a multi-strategy, multi-billion dollar hedge fund headquartered in New York City. While at Perry, Andrew was a member of a six-person illiquid special situations investment team where he focused on a variety of private investments across industries. Prior to working on illiquid investments, Andrew held primary responsibility for investing in healthcare products companies on Perry’s long/short equities team including biotechnology, pharmaceuticals, specialty pharmaceuticals, medical technology and equipment. Specifically, he engaged in strategies including long/short equities, merger arbitrage, credit and private equity. Before joining Perry, Andrew was a member of the biotechnology team in the equity research division at Goldman Sachs & Co. At Goldman, he worked for an Institutional Investor #2 ranked biotechnology team. Prior to Goldman, Andrew worked in the healthcare investment banking group at Merrill Lynch. He executed a variety of transactions while at Merrill Lynch, including mergers & acquisitions, debt/equity financings and IPOs. Andrew earned a Bachelor of Science in Biochemistry from the University of Virginia, where he was an Echols Scholar and graduated Phi Beta Kappa.